The estimated Net Worth of Scott Koenig is at least $5 Million dollars as of 15 February 2024. Dr Koenig owns over 42,341 units of Macrogenics Inc stock worth over $3,952,957 and over the last 11 years he sold MGNX stock worth over $0. In addition, he makes $1,045,415 as CEO und Pres & Director at Macrogenics Inc.
Sign up
Dr D MGNX stock SEC Form 4 insiders trading
Dr has made over 14 trades of the Macrogenics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 42,341 units of MGNX stock worth $153,274 on 15 February 2024.
The largest trade he's ever made was exercising 133,163 units of Macrogenics Inc stock on 11 March 2020 worth over $125,173. On average, Dr trades about 17,287 units every 78 days since 2013. As of 15 February 2024 he still owns at least 1,091,977 units of Macrogenics Inc stock.
You can see the complete history of Dr Koenig stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Scott Koenig M.D., Ph.D. biography
Dr. Scott Koenig M.D., Ph.D. is the CEO, Pres & Director at Macrogenics Inc.
What is the salary of Dr D?
As the CEO und Pres & Director of Macrogenics Inc, the total compensation of Dr D at Macrogenics Inc is $1,045,415. There are no executives at Macrogenics Inc getting paid more.
How old is Dr D?
Dr D is 69, he's been the CEO und Pres & Director of Macrogenics Inc since . There are no older and 9 younger executives at Macrogenics Inc.
What's Dr D's mailing address?
Scott's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at Macrogenics Inc
Over the last 11 years, insiders at Macrogenics Inc have traded over $27,036,278 worth of Macrogenics Inc stock and bought 4,026,274 units worth $39,875,062 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Target N Vbb Biotech Ag Bio... und Edward Hurwitz. On average, Macrogenics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $132,068. The most recent stock trade was executed by Jay Philip Siegel on 20 May 2024, trading 4,500 units of MGNX stock currently worth $16,290.
What does Macrogenics Inc do?
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
What does Macrogenics Inc's logo look like?
Complete history of Dr Koenig stock trades at Applied Genetic Technologies Corp, GlycoMimetics Inc und Macrogenics Inc
Macrogenics Inc executives and stock owners
Macrogenics Inc executives and other stock owners filed with the SEC include:
-
Dr. Scott Koenig M.D., Ph.D.,
CEO, Pres & Director -
Dr. Scott Koenig,
CEO, Pres & Director -
Dr. Ezio Bonvini,
Sr. VP of Research & Chief Scientific Officer -
James Karrels,
Sr. VP, CFO & Corp. Sec. -
Eric Blasius Risser,
Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer -
Dr. Stephen L. Eck,
Sr. VP of Clinical Devel. & Chief Medical Officer -
Dr. Stephen L. Eck M.D., Ph.D.,
Sr. VP of Clinical Devel. & Chief Medical Officer -
Dr. Christopher Shayne James M.D.,
VP of Investor Relations & Corp. Communications -
Lynn Cilinski,
VP, Controller & Treasurer -
Dr. Thomas M. Spitznagel,
Sr. VP of BioPharmaceutical Devel. & Manufacturing -
Jeffrey Stuart Peters,
Sr. VP & Gen. Counsel -
Anna Krassowska Ph.D.,
VP of Investor Relations & Corp. Communications -
David C Stump,
Director -
Kenneth Galbraith,
Director -
Lynn Cilinski,
VP, Controller and Treasurer -
Atul Saran,
See remarks -
Scott Thomas Jackson,
Director -
Karen Jean Ferrante,
Director -
Edward Hurwitz,
Director -
Matthew K Fust,
Director -
Ezio Bonvini,
Sr VP, Research & CSO -
Paulo F Costa,
Director -
Scott Koenig,
President and CEO -
Jay Philip Siegel,
Director -
Jon Marc Wigginton,
Sr VP, Clinical Dev. & CMO -
Kathryn E Stein,
Senior VP, Prd Dev & Reg Aff -
Stanford John Stewart,
V P, Clinical Oncology -
Biopharma Partners Iii Lpal...,
-
Group Holdings (Sbs) Adviso...,
-
Eran Nadav,
Director -
Arnold L Oronsky,
Director -
James Karrels,
SVP, CFO and Secretary -
William K Heiden,
Director -
Stephen L. Eck,
Chief Medical Officer -
Federica F. O'brien,
Director -
Eric Blasius Risser,
Chief Operating Officer -
Jeffrey Stuart Peters,
Senior VP and General Counsel -
Thomas Spitznagel,
Sr VP, Technical Ops -
Target N Vbb Biotech Ag Bio...,
-
Margaret Liu,
Director -
Meenu Chhabra,
Director